메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국임상약학회 한국임상약학회지 한국임상약학회지 제14권 제2호
발행연도
2004.1
수록면
85 - 90 (6page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Bisoprolol, one of the 1-adrenorecepter antagonist, has been used for the treatment of mild to moderate essential hypertension and stable angina pectoris. The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life, 9~12 hr, which allows once-daily administration. The bioequivalence of two bisoprolol preparations was evaluated according to the guidelines of Korea Food & Drug Administration (KFDA). The test product was Concor tablet�� made by Newgenpharm and the reference product was Monocor tablet�� made by Wyeth Korea. Twenty healthy male subjects, 23.8 (21-30) years old and 63.8(52-92) kg, were randomly divided into two groups and a randomized 2×2 cross-over study was employed. After two tablets containing 10 mg bisoprolol hemifumarate were orally administered, blood was taken at predetermined time intervals and the concentration of bisoprolol in plasma was determined using an HPLC method with fluorescence detector. Two pharmacokinetic parameters, AUCt and Cmax were calculated and analyzed statistically for the evaluation of bioequivalence of the two products. Analysis of variance was carried out using logarithmically transformed parameter values. The 90% confidence intervals of AUCt and Cmax were log 0.95~log 1.04 and log 0.96~log 1.07, respectively. These values were within the acceptable bioequivalence intervals of log 0.8~log 1.25. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating that Concor tablet is bioequivalent to Monocor tablet.

목차

등록된 정보가 없습니다.

참고문헌 (4)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0